Alternatives to RestorLife Med

Mondae is built for someone who wants the decisions made up front and then left alone. Price, plan length and — unusually — which of six named compounding pharmacies fills the prescription are all settled before intake, the questionnaire is asynchronous with no video call to book, and it serves all 50 states. The rate is $115 a month for compounded semaglutide and $145 for compounded tirzepatide, with no membership fee stacked on top and no increase as you titrate: 'your dose may increase, but your price is fixed.' For a working parent that predictability is the whole point, because a dose-priced plan can quietly double between a starting and a maintenance dose. The pharmacy disclosure is the standout — Boudreaux, Rush, Hallandale, Greenwich, Align and VialsRx, named and selectable, where most of this category names none — with the honest caveat that Mondae itself flags: each ships to different states and formulations 'may contain additional additives.' Both prices were verified from a rendered page rather than a marketing card, because the raw HTML ships a '$NNN' placeholder, and they agree with the homepage card and the page's own structured data. What is absent is routine: no named clinician behind the contracted Bask Telehealth network, no labs, no refunds once medication is dispensed, and nothing addressing postpartum recovery, breastfeeding or PCOS.

For a working mother the appeal here is logistics as much as money: a fully online intake with no video call to schedule, all 50 states, and one flat charge per month that covers the visit, the plan, the medication and shipping — held at the same price whatever dose you end up on. Month to month that is $79 for compounded semaglutide and $109 for compounded tirzepatide; the $69 the homepage headlines under a countdown timer is the twelve-month tier, and $95 is its tirzepatide equivalent. Flat-by-dose is the part that actually protects a budget, because dose-priced providers routinely double between a starting and a maintenance dose. Two things to weigh against that. The off-ramp is narrow: subscriptions auto-renew, canceling means emailing care@leanmeds.com at least 48 hours before the processing date, and the order stops being refundable the moment you submit the medical intake. And the operator named throughout its own Terms — Trinity HealthCare Supply, LLC — is the company FDA wrote to on 8 June 2026 under its other brand, altRx, for labeling compounded vials with its own name when it was not the compounder and for calling compounded GLP-1s 'clinically proven.' That letter concerns altrx.com, not this site, but it is the same legal entity at the same Miami suite, and no pharmacy or clinician is named here either.

Every price TrimRx advertises is a starting price, and it publishes no ending one. The homepage shows 'Starting at $179' semaglutide and 'Starting at $259' tirzepatide; a second TrimRx funnel was advertising 'Starting at $149' the same day; trimrx.com/pricing renders blank; and the Terms contain no pricing at all. There is no ongoing rate on this site to find. The flat-at-every-dose promise is real — checkout says 'Same Price. All Dosage Levels.' — but the intake runs 35 screens and never once asks whether you are pregnant or breastfeeding.

Compounded semaglutide at $79 a month and tirzepatide at $119, month to month, with no dose-based increase and — checked in its own checkout data rather than taken on trust — a renewal price identical to the joining price. That last part is rarer than it should be. Two things the homepage will not tell you. The $49 and $99 it advertises are the twelve-month totals divided by twelve, not a monthly rate you can start on, and the countdown beside them is not a real deadline: it read August 15th and then August 20th within the same hour. The larger caveat is corporate. NextMeds is operated by Trinity HealthCare Supply, LLC, which also runs Lean Meds, altRx and Trinity Meds, and that operator holds an open FDA warning letter.

Novi's month-to-month rates are $149 semaglutide and $179 tirzepatide, flat at every dose — but almost every number the site advertises is a prepay term price divided by its term. The '$88/mo' headline on Novi's own product page is the twelve-month row, and its homepage quotes '$133/mo' under a countdown, a figure that is not a monthly price on either product page. Its intake then serves a higher variant again. Its Terms require a three-month non-refundable commitment while its help center says there are no commitments at all, so the two things you most need to know — what leaves the account, and when you can stop — are the two things Novi contradicts itself on.

The one confirmed nationwide pick in this batch — all 50 states, explicitly stated — with a $168/mo semaglutide, $268/mo tirzepatide month-to-month rate that only drops to $129/$199 on a full year prepaid upfront.

Compounded semaglutide at $190 a month and tirzepatide at $275, the same price at every dose, medication and clinician access included — and then something no one else here does: the price drops the longer you stay consistent. Its own pricing page publishes the whole ladder, 10% off at a ten-day streak, 20% at twenty, 30% at thirty, which takes semaglutide down to $133 and tirzepatide to $192. Two things to weigh. The $190 and $275 are what you actually start on, so treat the low numbers as a discount you have to earn and keep. And nowhere on that page does it say what counts as a streak or what breaks one, which is the first thing worth asking.

Priced by how long you commit rather than how much you take: compounded semaglutide is $269 a month without a commitment and $199 on a 48-week plan, with tirzepatide at $369 and $299, and the 12- and 24-week plans between at $249 and $229 for semaglutide. The advertised "from $199 per month" is the year-long option, so the honest uncommitted figure is about 35% higher, and the longer plans ship every twelve weeks. Because price is set by commitment rather than dose, the bill does not climb as you titrate — a real advantage if you are budgeting ahead. Two things deserve attention first. The product pages never name the molecule at all, selling only a "GLP-1" and a "GLP-1 + GIP", with semaglutide and tirzepatide appearing nowhere except the terms. And the same three testimonials run on both product pages, one about the dual agonist while sitting on the semaglutide page, beneath a "Loved by 800+ women" line carrying no source. No time to first dose is published.

Flat at every dose - $99 semaglutide, $134 tirzepatide, all fifty states - which makes the annual math trivial. The site never names its operating company.